Shark IgNAR-derived binding domains as potential diagnostic and therapeutic agents

Area of Science:

• Biotechnology
• Immunology
• Drug Discovery

Background:

• Monoclonal antibodies (mAbs) are successful therapeutics but have limitations.
• mAb limitations include large size, poor tissue penetration, and production costs.
• Alternative antigen-binding molecules are needed for specific applications.

Purpose of the Study:

• To explore shark-derived variable new antigen receptors (VNARs) as an alternative to mAbs.
• To evaluate VNARs for therapeutic, diagnostic, and biotechnological applications.

Main Methods:

• Investigated the characteristics of VNARs, focusing on their binding properties and stability.
• Compared VNARs to conventional mAbs in terms of size, specificity, affinity, and stability.

Main Results:

• VNARs exhibit high specificity and affinity for antigens despite their small size.
• VNARs demonstrate superior tissue penetration and stability compared to mAbs.
• VNARs can access epitopes inaccessible to conventional mAbs.

Conclusions:

• VNARs are a viable alternative to mAbs for applications where mAbs are suboptimal.
• VNARs show significant potential for therapeutic, diagnostic, and biotechnological advancements.